Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Eger

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
AIDS and Behavior|February 6, 2024
Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border MetroplexWilliam H Eger, Angela R Bazzi, Chad J Valasek, et al.
Viruses|January 8, 2025
Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention StrategiesJaskaran S Cheema, Scott Suckow, Christian Ramers, et al.
The International Journal on Drug Policy|December 10, 2025
Integration of safer smoking equipment in U.S. syringe services programs: Qualitative insights from program staffWilliam H Eger, Shelby L Huffaker, Elana Forman, et al.
AIDS Patient Care and Stds|September 11, 2025
HIV Services Implementation Within US Syringe Services Programs: A Qualitative ExplorationAlexis M Roth, Elana Forman, Christopher F Akiba, et al.
Harm Reduction Journal|August 29, 2024
Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulterationWilliam H Eger, Marina Plesons, Tyler S Bartholomew, et al.
Research Square|August 16, 2024
Protective or potentially harmful? Altering drug consumption behaviors in response to xylazine adulterationWilliam H Eger, Marina Plesons, Tyler S Bartholomew, et al.
Nature Medicine|March 19, 2025
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trialAmanda K Rudman Spergel, Jintanat Ananworanich, Ruiting Guo, et al.
The International Journal on Drug Policy|July 24, 2025
Modeling the impact of changing drug markets and structural determinants on HCV and/or HIV transmission among people who inject drugs in the United States: A rural and urban comparisonNatasha K Martin, Daniela Abramovitz, William H Eger, et al.
Drug and Alcohol Dependence Reports|July 21, 2025
Psychosocial consequences of xylazine and implications for harm reduction servicesMarina Plesons, William H Eger, Erika L Crable, et al.
The International Journal on Drug Policy|September 15, 2024
A mixed methods study to inform fatal overdose prevention in San Diego, California: Perspectives from people who use drugsKatie Bailey, Arielle Schecter, William H Eger, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
AIDS and Behavior|February 6, 2024
Long-acting Injectable PrEP Interest and General PrEP Awareness among People who Inject Drugs in the San Diego-Tijuana Border MetroplexWilliam H Eger, Angela R Bazzi, Chad J Valasek, et al.
Viruses|January 8, 2025
Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention StrategiesJaskaran S Cheema, Scott Suckow, Christian Ramers, et al.
The International Journal on Drug Policy|December 10, 2025
Integration of safer smoking equipment in U.S. syringe services programs: Qualitative insights from program staffWilliam H Eger, Shelby L Huffaker, Elana Forman, et al.
AIDS Patient Care and Stds|September 11, 2025
HIV Services Implementation Within US Syringe Services Programs: A Qualitative ExplorationAlexis M Roth, Elana Forman, Christopher F Akiba, et al.
Harm Reduction Journal|August 29, 2024
Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulterationWilliam H Eger, Marina Plesons, Tyler S Bartholomew, et al.
Research Square|August 16, 2024
Protective or potentially harmful? Altering drug consumption behaviors in response to xylazine adulterationWilliam H Eger, Marina Plesons, Tyler S Bartholomew, et al.
Nature Medicine|March 19, 2025
mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trialAmanda K Rudman Spergel, Jintanat Ananworanich, Ruiting Guo, et al.
The International Journal on Drug Policy|July 24, 2025
Modeling the impact of changing drug markets and structural determinants on HCV and/or HIV transmission among people who inject drugs in the United States: A rural and urban comparisonNatasha K Martin, Daniela Abramovitz, William H Eger, et al.
Drug and Alcohol Dependence Reports|July 21, 2025
Psychosocial consequences of xylazine and implications for harm reduction servicesMarina Plesons, William H Eger, Erika L Crable, et al.
The International Journal on Drug Policy|September 15, 2024
A mixed methods study to inform fatal overdose prevention in San Diego, California: Perspectives from people who use drugsKatie Bailey, Arielle Schecter, William H Eger, et al.
Pageof 9